Reuters reveals India’s PharmEasy plans $200 million fundraising at decrease valuation

Reuters was first to report that Indian drug and medical providers startup PharmEasy is in talks with buyers to lift $200 million, however at a valuation that might be 15% and even 25% decrease than final 12 months’s $5.1 billion. Indian startups have been jolted by unsure international and home inventory markets and rising investor skepticism over what they are saying are sky-high valuations, making it tough for PharmEasy to lift funds at similar or the next valuation.